MapLight Therapeutics (MPLT) Common Equity (2024 - 2025)
MapLight Therapeutics (MPLT) reported Common Equity of $458.4 million for Q4 2025, up 336.73% on a YoY basis from $105.0 million in Q4 2024, and up 267.18% sequentially from -$274.2 million in Q3 2025.
MapLight Therapeutics (MPLT) Common Equity (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Common Equity data on file, last reported at $458.4 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 336.73% year-over-year to $458.4 million; the trailing twelve-month figure through Dec 2025 stood at $458.4 million (up 336.73% YoY), and the FY2025 full-year result was $458.4 million, up 336.73% from the prior year.
- Common Equity grew to $458.4 million in Q4 2025, from -$274.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $458.4 million in Q4 2025 to a low of -$274.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 458.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 458.37 Mn |
| Sep 30, 2025 | -274.18 Mn |
| Dec 31, 2024 | -193.63 Mn |
| Sep 30, 2024 | -172.37 Mn |